ANDREA BLEVINS: Open Payments
NPI 1174601017 · GREENSBORO, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$732 in 18 payments from 8 companies in 2025. Trend: 2023 $838 · 2024 $892 · 2025 $732
Food & beverage: $732
| Company | Payments | Amount |
|---|---|---|
| Lilly USA, LLC | 2 | $237 |
| AstraZeneca Pharmaceuticals LP | 4 | $185 |
| Corcept Therapeutics | 3 | $158 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $49 |
| ABBVIE INC. | 2 | $46 |
| Otsuka America Pharmaceutical, Inc. | 2 | $28 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $15 |
| Novo Nordisk Inc | 1 | $15 |
Products named: AIRSUPRA, Korlym, MOUNJARO, ZEPBOUND, CAPLYTA, VRAYLAR, REXULTI, XIFAXAN.
Industry payments across NC — which companies pay providers there.
